The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Tumor suppressor p53: analysis of wild-type and mutant p53 complexes.
Open accessAbstract
It has been suggested that the dominant effect of mutant p53 on tumor progression may reflect the mutant protein binding to wild-type p53, with inactivation of suppressor function. To date, evidence for wild-type/mutant p53 complexes involves p53 from different species. To investigate wild-type/mutant p53 complexes in relation to natural tumor progression, we sought to identify intraspecific complexes, using murine p53. The mutant phenotype p53-246(0) was used because this phenotype is immunologically distinct from wild-type p53-246+ and thus permits immunological analysis for wild-type/mutant p53 complexes. The p53 proteins were derived from genetically defined p53 cDNAs expressed in vitro and also from phenotypic variants of p53 expressed in vivo. We found that the mutant p53 phenotype was able to form a complex with the wild type when the two p53 variants were cotranslated. When mixed in their native states (after translation), the wild-type and mutant p53 proteins did not exhibit any binding affinity for each other in vitro. Under identical conditions, complexes of wild-type human and murine p53 proteins were formed. For murine p53, both the wild-type and mutant p53 proteins formed high-molecular-weight complexes when translated in vitro. This oligomerization appeared to involve the carboxyl terminus, since truncated p53 (amino acids 1 to 343) did not form complexes. We suggest that the ability of the mutant p53 phenotype to complex with wild type during cotranslation may contribute to the transforming function of activated mutants of p53 in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The p53 proto-oncogene can act as a suppressor of transformation
Finlay, C. A., Hinds, P. W., & Levine, A. J. (1989) · Cell · doi:10.1016/0092-8674(89)90045-7 · Cited by 1,987
Cited by
Weinberg, R. A. (1991) · Science · doi:10.1126/science.1659741 · Cited by 1,756
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132
Yin, Y., Tainsky, M. A., Bischoff, F. Z., Strong, L. C., & Wahl, G. M. (1992) · Cell · doi:10.1016/0092-8674(92)90244-7 · Cited by 1,089
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069
Rivlin, N., Brosh, R., Oren, M., & Rotter, V. (2011) · Genes & Cancer · doi:10.1177/1947601911408889 · Cited by 1,033
Awakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881
Regulation of the specific DNA binding function of p53
Hupp, T. R., Meek, D. W., Midgley, C. A., & Lane, D. P. (1992) · Cell · doi:10.1016/0092-8674(92)90562-q · Cited by 909
p53 regulates epithelial–mesenchymal transition and stem cell properties through modulating miRNAs
Chang, C.-J., Chao, C.-H., Xia, W., Yang, J.-Y., Xiong, Y., Li, C.-W., Yu, W.-H., Rehman, S. K., Hsu, J. L., Lee, H.-H., et al. (2011) · Nature Cell Biology · doi:10.1038/ncb2173 · Cited by 745
Harris, C. C. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.20.1442 · Cited by 680
Twenty years of p53 research: structural and functional aspects of the p53 protein
May, P., & May, E. (1999) · Oncogene · doi:10.1038/sj.onc.1203285 · Cited by 663
Milner, J., & Medcalf, E. A. (1991) · Cell · doi:10.1016/0092-8674(91)90384-b · Cited by 612
Self-citationWild-type p53 activates transcription in vitro
Farmer, G., Bargonetti, J., Zhu, H., Friedman, P., Prywes, R., & Prives, C. (1992) · Nature · doi:10.1038/358083a0 · Cited by 579
Kurman, R. J., & Shih, I.-M. (2008) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e318161e4f5 · Cited by 460
Mutations in the p53 gene: An early marker of neoplastic progression in ulcerative colitis
Brentnall, T. A., Crispin, D. A., Rabinovitch, P. S., Haggitt, R. C., Rubin, C. E., Stevens, A. C., & Burmer, G. C. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90161-9 · Cited by 432
p73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells
Di Como, C. J., Gaiddon, C., & Prives, C. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1438 · Cited by 417
A comparison of the biological activities of wild‐type and mutant p53
Zambetti, G. P., & Levine, A. J. (1993) · The FASEB Journal · doi:10.1096/fasebj.7.10.8344485 · Cited by 413
Shaulian, E., Zauberman, A., Ginsberg, D., & Oren, M. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.12.5581 · Cited by 342
Gain-of-function mutant p53 in cancer progression and therapy
Zhang, C., Liu, J., Xu, D., Zhang, T., Hu, W., & Feng, Z. (2020) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaa040 · Cited by 334
Donehower, L. A., & Bradley, A. (1993) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(93)90004-v · Cited by 333
Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis.
Franklin, W. A., Gazdar, A. F., Haney, J., Wistuba, I. I., La Rosa, F. G., Kennedy, T., Ritchey, D. M., & Miller, Y. E. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119748 · Cited by 330
Willis, A., Jung, E. J., Wakefield, T., & Chen, X. (2004) · Oncogene · doi:10.1038/sj.onc.1207396 · Cited by 330
Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy
Yue, X., Zhao, Y., Xu, Y., Zheng, M., Feng, Z., & Hu, W. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.03.030 · Cited by 308
The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth.
Finlay, C. A. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.1.301 · Cited by 311
Kim, M. P., & Lozano, G. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.185 · Cited by 311
DNA-dependent protein kinase acts upstream of p53 in response to DNA damage
Woo, R. A., McLure, K. G., Lees-Miller, S. P., Rancourt, D. E., & Lee, P. W. K. (1998) · Nature · doi:10.1038/29343 · Cited by 309
Mechanisms of protein-folding diseases at a glance
Valastyan, J. S., & Lindquist, S. (2014) · Disease Models & Mechanisms · doi:10.1242/dmm.013474 · Cited by 307
p53 gene mutations and protein accumulation in human ovarian cancer.
Kupryjańczyk, J., Thor, A. D., Beauchamp, R., Merritt, V, Edgerton, S. M., Bell, D. A., & Yandell, D. W. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.11.4961 · Cited by 289
The p53 protein is an unusually shaped tetramer that binds directly to DNA.
Friedman, P. N., Chen, X., Bargonetti, J., & Prives, C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3319 · Cited by 264
Ambs, S., Hussain, S. P., & Harris, C. C. (1997) · The FASEB Journal · doi:10.1096/fasebj.11.6.9194524 · Cited by 233
C-terminal modifications regulate MDM2 dissociation and nuclear export of p53
Carter, S., Bischof, O., Dejean, A., & Vousden, K. H. (2007) · Nature Cell Biology · doi:10.1038/ncb1562 · Cited by 225
Inhibition of p53 DNA binding by human papillomavirus E6 proteins
Lechner, M. S., & Laimins, L. A. (1994) · Journal of Virology · doi:10.1128/jvi.68.7.4262-4273.1994 · Cited by 195
Metadata
- Authors
- Milner, J., Medcalf, E. A., & Cook, A. C.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 1991-01
- Volume
- 11
- Issue
- 1
- Pages
- 12-19
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W1839476071
- Cited by
- 243
- References
- 1
- FWCI
- 9.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.